Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > LSU Study

<< Previous

Bullboard Posts

Next >>

Comment by JMark80on Sep 05, 2020 12:04pm

287 Views

Post# 31515493

RE:RE:RE:LSU Study

Kaly should have waited to see results of NO gas for treating Covid first - nothing to get excited about. It's only worth developing if the government will pay for it, and it is certainly not worth re-structuring a company around. Look at financing undersubscribed at $.015 with warrant. There's no interest! R107 is worth further development for PAH, but Kalytera can't afford it.

<< Previous

Bullboard Posts

Next >>

AI companies to invest in